Welcome!

News Feed Item

Horizon Pharma Reports First Quarter 2014 Financial Results Exceeding Expectations and Raises 2014 Full-Year Guidance

Net Revenues of $51.9 Million, Adjusted EBITDA of $11.0 Million and Adjusted Non-GAAP Net Income of $11.0 Million, or $0.13 Non-GAAP Diluted Earnings per Share

DEERFIELD, IL -- (Marketwired) -- 05/09/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the first quarter ended March 31, 2014.

First Quarter 2014 Financial Highlights

  • Gross and net sales were a record $92.2 million and $51.9 million, respectively, representing an overall gross to net revenue deduction of 43.7%.
  • First quarter 2014 VIMOVO net sales were $34.0 million.
  • First quarter 2014 net sales of DUEXIS and RAYOS were $13.9 million and $3.3 million, respectively.
  • Adjusted EBITDA was $11.0 million after excluding the impact of $4.0 million in Vidara acquisition related expenses.
  • Adjusted non-GAAP net income was $11.0 million, or $0.16 non-GAAP basic earnings per share and $0.13 non-GAAP diluted earnings per share.
  • On a GAAP basis, net loss in the first quarter of 2014 was $206.3 million, which includes a non-cash charge of $204.0 million related to the increase in fair value of the embedded derivative associated with the Company's convertible senior notes due to an increase in the market value of the Company's common stock during the first quarter.
  • The Company generated $4.3 million in adjusted cash from operating activities, excluding payments made in connection with the Vidara acquisition.
  • Cash and cash equivalents at March 31, 2014 were $103.4 million.

Financial Guidance

  • For 2014, the Company expects net revenues in the range of $270 to $280 million, which assumes the Vidara acquisition closes by July 31, 2014 and includes ACTIMMUNE revenues for the period of August through December 2014. This includes net revenues in the range of $245 to $255 million for the Company's base business, which includes DUEXIS, VIMOVO, RAYOS and LODOTRA.
  • For 2014, the Company expects adjusted EBITDA (excluding Vidara acquisition related expenses, step up in inventory required under purchase accounting related to ACTIMMUNE and other potential special items or substantive events) to be in the range of $80 to $90 million, which assumes the Vidara acquisition closes by July 31, 2014 and includes ACTIMMUNE results for the period of August through December 2014.

"2014 is off to a great start with record revenues for the quarter and our first ever non-GAAP quarterly profit," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "VIMOVO results were above our expectations, with $34.0 million in net revenue in the first quarter, our first full quarter of marketing VIMOVO after acquiring it from AstraZeneca in November 2013. As a result of our outperformance in the quarter and including an expected five months of ACTIMMUNE sales, we have increased our net revenues and adjusted EBITDA guidance for the year."

Mr. Walbert continued, "We are also making good progress in activities related to the proposed Vidara acquisition, including the early termination of the HSR waiting period, and currently expect we will be in a position to close the transaction this summer."

First Quarter 2014 Financial Results

During the three months ended March 31, 2014, gross and net sales were $92.2 million and $51.9 million, respectively, compared to $10.7 million and $8.7 million, respectively, during the three months ended March 31, 2013. The Company reaffirms its expectation of mid-forty percent gross to net discounts across its portfolio in 2014.

VIMOVO gross and net sales during the three months ended March 31, 2014 were $50.0 million and $34.0 million, respectively, after deducting sales discounts and allowances of $16.0 million, including co-pay assistance costs of $4.6 million. The Company began promotion of VIMOVO with its rheumatology sales force on November 26, 2013 and began commercialization through its primary care sales force on January 2, 2014. According to data from IMS Health, new prescriptions for VIMOVO increased 10% in January, 18% in February and 15% in March versus the prior month, respectively, as the installed base of prior VIMOVO prescribers were very responsive to active promotion for the first time in years and the commercial business outgrew the decline of the government and cash business. According to data from IMS Health, total prescriptions for VIMOVO in the first quarter of 2014 were 69,368.

DUEXIS gross and net sales during the three months ended March 31, 2014 were $36.4 million and $13.9 million, respectively, after deducting sales discounts and allowances of $22.5 million, including co-pay assistance costs of $11.3 million, compared to gross and net sales of $6.7 million and $4.9 million, respectively, during the three months ended March 31, 2013. The increase in DUEXIS sales during the three months ended March 31, 2014 compared to the prior year period was primarily the result of prescription volume growth driven by expansion of the field sales organization and product price increases implemented during the course of 2013 and in January 2014. DUEXIS sales discounts and allowances increased from the prior year period and from the fourth quarter of 2013 primarily due to higher co-pay costs as a result of the Company's strategy of keeping patients in spite of higher deductibles and managed care plan changes at the beginning of the calendar year, and higher managed care rebates in the quarter driven by channel mix. The Company expects a moderating of DUEXIS sales discounts and allowances in the coming quarters as patients meet their plan deductibles and co-pay costs are reduced. According to data from IMS Health, total prescriptions for DUEXIS in the first quarter of 2014 were 53,368, versus 39,365 in the first quarter of 2013, an increase of 36%.

RAYOS gross and net sales were $5.1 million and $3.3 million, respectively, during the three months ended March 31, 2014 after deducting sales discounts and allowances of $1.8 million, including co-pay assistance costs of $0.8 million, compared to gross and net sales of $0.4 million and $0.3 million, respectively, during the three months ended March 31, 2013. The increase in RAYOS sales during the three months ended March 31, 2014 compared to the prior year period was primarily attributable to increased volume driven by the expansion of the Company's sales force focused on RAYOS and product price increases implemented during the course of 2013 and in January 2014. According to data from IMS Health, total prescriptions for RAYOS in the first quarter of 2014 were 2,945, versus 1,152 in the first quarter of 2013.

LODOTRA gross and net sales during the three months ended March 31, 2014 were $0.7 million compared to gross and net sales of $3.6 million and $3.5 million, respectively, during the three months ended March 31, 2013. The decrease in LODOTRA sales during the three months ended March 31, 2014 compared to the prior year period was the result of timing of product shipments to the Company's European distribution partner, Mundipharma. LODOTRA sales to Mundipharma occur at the time the Company ships product based on Mundipharma's estimated requirements. Accordingly, LODOTRA sales are not linear or directly tied to Mundipharma sales to the market and can therefore fluctuate from quarter to quarter.

Net loss for the first quarter of 2014 was $206.3 million, or $3.07 per share based on 67,138,463 weighted average shares outstanding, compared to a net loss of $22.2 million, or $0.36 per share based on 61,939,822 weighted average shares outstanding, during the first quarter of 2013. During the first quarter of 2014, the Company recorded a $204.0 million non-cash charge related to the increase in the fair value of the embedded derivative associated with the Company's convertible senior notes. The increase in fair value was primarily due to a $7.50 per share increase in the market value of the Company's common stock between December 31, 2013 and March 31, 2014.

Non-GAAP net income for the first quarter of 2014 was $6.9 million, or $0.10 per share basic and $0.08 per share diluted, compared to a non-GAAP net loss of $18.7 million, or $0.30 per share basic and diluted, during the first quarter of 2013. Excluding expenses associated with the Vidara acquisition, adjusted non-GAAP net income for the first quarter of 2014 was $11.0 million, or $0.16 per share basic and $0.13 per share diluted. Refer to the section of this press release below titled, "Note Regarding Use of Non-GAAP Financial Measures."

The Company had cash and cash equivalents of $103.4 million at March 31, 2014. Excluding payments made in connection with the Vidara acquisition, the Company generated $4.3 million in cash from operating activities during the first quarter of 2014. The Company also generated $24.2 million in cash during the first quarter of 2014 from financing activities, primarily as a result of proceeds from warrant exercises.

Gross profit margins improved to 85% of net sales during the first quarter of 2014 from 57% in the first quarter of 2013, including the impact of depreciation and intangible amortization expense. Excluding depreciation and intangible amortization expense, adjusted gross profit margins were 95% in the first quarter of 2014 compared to 76% in the first quarter of 2013. Higher average selling prices, product sales mix and the increase in net sales which spreads fixed amortization amounts over a larger base were primarily responsible for the improvement in the current period.

Total operating expenses increased to $42.7 million in the first quarter of 2014 from $23.5 million in the first quarter of 2013. $12.4 million of the increase was attributable to sales and marketing, with the majority driven by expansion of the Company's field sales force as a result of the VIMOVO acquisition. General and administrative expenses increased $6.3 million in the first quarter of 2014 versus the first quarter of 2013, with approximately $4.0 million related to the Vidara acquisition.

Interest expense increased by net $0.6 million to $4.2 million during the three months ended March 31, 2014, from $3.6 million during the three months ended March 31, 2013. The increase in interest expense was primarily attributable to higher debt discount expenses of $1.4 million, offset by $0.8 million in lower interest expense as a result of lower borrowing costs under the Company's 5.0% convertible senior notes due 2018, compared to borrowing costs under the Company's prior senior secured loan facility which was retired in November 2013.

Note Regarding Use of Non-GAAP Financial Measures

Horizon provides certain financial measures such as non-GAAP net income (loss) and non-GAAP net income (loss) per share, gross profit margins and cash from operations, including further adjustments to these measures, that include adjustments to GAAP figures. These adjustments to GAAP exclude transaction related expenses as well as non-cash items such as stock compensation, depreciation and amortization, non-cash interest expense, and other non-cash adjustments such as the increase or decrease in the fair value of the embedded derivative associated with the Company's convertible senior notes. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are also used and provided by Horizon as a non-GAAP financial measure. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of operational results and trends. In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the financial statements portion of this press release where the Company has provided a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. However, the Company has not provided a reconciliation of full year 2014 adjusted EBITDA outlook to a net income (loss) outlook because certain items that are a component of net income (loss) but not part of adjusted EBITDA, such as the gain (loss) on derivative revaluation associated with the convertible senior notes, are not in our control and cannot be reasonably projected due to the significant impact of changes in Horizon's stock price on that component of net income (loss).

Conference Call

At 8:00 a.m. Eastern Time today, Horizon's management will host a live conference call and webcast to review the Company's financial and operating results and provide a general business update.

The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 29164068. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 29164068.

About Horizon Pharma

Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, VIMOVO® and RAYOS®/LODOTRA®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines or companies where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding expected 2014 net revenue and adjusted EBITDA, expectations regarding future DUEXIS sales discounts and allowances for the remainder of 2014, the expected timing for closing of the Vidara acquisition and the on-going commercialization of DUEXIS, VIMOVO and RAYOS and future commercialization of ACTIMMUNE. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, risks regarding Horizon's ability to commercialize products successfully, whether commercial data regarding DUEXIS, VIMOVO, RAYOS and ACTIMMUNE in the United States for any historic periods are indicative of future results, Horizon's ability to comply with post-approval regulatory requirements, Horizon's ability to enforce its intellectual property rights to its products, whether and when Horizon will be able to satisfy the conditions precedent to close its proposed merger with Vidara, Horizon's ability to execute on its plan to grow through acquisition of or in-licensing additional products or companies where it can execute a targeted commercial approach among specific target physicians and whether any such acquisitions or in-licensing transactions will leverage the Company's commercial strengths and infrastructure. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update or revise these statements, except as may be required by law.

Additional Information and Where to Find It

In connection with the proposed transaction, Horizon and Vidara will be filing documents with the SEC, including the filing by Horizon of a preliminary and definitive proxy statement/prospectus relating to the proposed transaction and the filing by Vidara of a registration statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Horizon stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HORIZON, VIDARA AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, by directing a request to Horizon's Investor Relations department at Horizon Pharma, Inc., Attention: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015 or to Horizon's Investor Relations department at 224-383-3000 or by email to [email protected]. Investors and security holders may obtain free copies of the documents filed with the SEC on Horizon's website at www.horizonpharma.com under the heading "Investors" and then under the heading "SEC Filings."

Horizon and its directors and executive officers and Vidara and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Horizon in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of Horizon is also included in Horizon's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 13, 2014. These documents are available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Horizon as described above.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.



                   CONDENSED CONSOLIDATED BALANCE SHEETS

              (in thousands, except share and per share data)

                                                           As of
                                               ----------------------------
                                                 March 31,     December 31,
                                                    2014           2013
                                               -------------  -------------
                                                        (Unaudited)
Assets
Current assets
  Cash and cash equivalents                    $     103,374  $      80,480
  Restricted cash                                        738            738
  Accounts receivable, net                            40,100         15,958
  Inventories, net                                     9,432          8,701
  Prepaid expenses and other current assets            9,105          4,888
                                               -------------  -------------
    Total current assets                             162,749        110,765
  Property and equipment, net                          3,897          3,780
  Intangible assets, net                             125,992        131,094
  Other assets                                         6,496          6,957
                                               -------------  -------------
    Total assets                               $     299,134  $     252,596
                                               =============  =============
Liabilities and Stockholders' Equity
Current liabilities
  Accounts payable                             $      10,271  $       9,921
  Accrued expenses                                    44,712         24,049
  Accrued royalties                                   11,416          8,010
  Deferred revenues - current portion                  3,102          1,330
                                               -------------  -------------
    Total current liabilities                         69,501         43,310
Long-term liabilities

  Convertible debt, net                              112,774        110,762
  Derivative liability                               313,440        109,410
  Accrued royalties                                   21,576         24,982
  Deferred revenues, net of current                    8,017          9,686
  Deferred tax liabilities, net                        2,903          3,362
  Other long term liabilities                            166            166
                                               -------------  -------------
    Total liabilities                                528,377        301,678
                                               -------------  -------------

Commitments and Contingencies

Stockholders' equity
  Common stock, $0.0001 par value per share;
   200,000,000 shares authorized; 71,413,573
   and 66,097,417 shares issued and
   outstanding at March 31, 2014 and December
   31, 2013, respectively.                                 7              7
  Additional paid-in capital                         436,513        410,430
  Accumulated other comprehensive loss                (2,398)        (2,403)
  Accumulated deficit                               (663,365)      (457,116)
                                               -------------  -------------
    Total stockholders' deficit                     (229,243)       (49,082)
                                               -------------  -------------
    Total liabilities and stockholders' equity $     299,134  $     252,596
                                               =============  =============



              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

              (in thousands, except share and per share data)

                                               Three Months Ended March 31,
                                               ----------------------------
                                                    2014           2013
                                               -------------  -------------
                                                        (Unaudited)
Revenues
Gross sales                                    $      92,248  $      10,698
Sales discounts and allowances                       (40,322)        (2,005)
                                               -------------  -------------
  Net sales                                           51,926          8,693
                                               -------------  -------------

Cost of goods sold                                     7,619          3,769
                                               -------------  -------------
Gross profit                                          44,307          4,924
Operating Expenses
  Research and development                             2,833          2,198
  Sales and marketing                                 28,695         16,328
  General and administrative                          11,192          4,942
                                               -------------  -------------
    Total operating expenses                          42,720         23,468
                                               -------------  -------------
Operating income (loss)                                1,587        (18,544)

Interest expense, net                                 (4,207)        (3,603)
Foreign exchange loss                                    (38)          (905)
Loss on derivative fair value                       (204,030)             -
Other expense                                           (667)             -
                                               -------------  -------------
Loss before benefit for income taxes                (207,355)       (23,052)
Benefit for income taxes                              (1,105)          (881)
                                               -------------  -------------
Net loss                                       $    (206,250) $     (22,171)
                                               =============  =============

Net loss per share- basic and diluted          $       (3.07) $       (0.36)
                                               -------------  -------------
Weighted average shares outstanding used in
 calculating net loss per share - basic and
 diluted                                          67,138,463     61,939,822
                                               -------------  -------------



       RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET INCOME (LOSS)
             (in thousands, except share and per share amounts)

                                               Three Months Ended March 31,
                                               ----------------------------
                                                    2014           2013
                                               -------------  -------------
                                                        (Unaudited)

GAAP Net Loss                                  $    (206,250) $     (22,171)
Non-GAAP Adjustments
  Loss on derivative revaluation                     204,030              -
  Intangible amortization expense (net of tax
   effect)                                             4,680          1,324
  Stock-based compensation                             1,927          1,079
  Amortization of debt discount and deferred
   financing costs                                     2,333            910
  Depreciation expense                                   376            259
  Amortization of deferred revenue                      (161)           (68)
                                               -------------  -------------
    Total of non-GAAP adjustments                    213,185          3,504
                                               -------------  -------------
Non-GAAP Net Income (Loss)                     $       6,935  $     (18,667)
                                               =============  =============

Weighted average shares - basic                   67,138,463     61,939,822

Weighted average shares - diluted
  Weighted average shares - basic                 67,138,463     61,939,822
  Common stock equivalents                        15,961,807              -
                                               -------------  -------------
  Weighted average shares - diluted               83,100,270     61,939,822
                                               =============  =============

Non-GAAP Basic Earnings (Loss) per share:
GAAP net loss per common share-basic and
 diluted                                       $       (3.07) $       (0.36)
  Non-GAAP adjustments                                  3.17           0.06
                                               -------------  -------------
  Non-GAAP Basic Earnings (Loss) per share     $        0.10  $       (0.30)

Non-GAAP Diluted Net Income (Loss) Per Share:
Non-GAAP net income (loss) per common share-
 basic                                         $        0.10  $       (0.30)
  Dilutive earnings per share effect of common
   stock equivalents                                   (0.02)             -
                                               -------------  -------------
  Non-GAAP net income (loss) per common share-
   diluted                                     $        0.08  $       (0.30)


Adjustments to Non-GAAP Net Income (Loss)
  Adjustment for Vidara acquisition expenses   $       4,049  $           -
                                               -------------  -------------
    Total of non-GAAP adjustments                    217,234          3,504
                                               -------------  -------------
Adjusted Non-GAAP Net Income (Loss)            $      10,984  $     (18,667)
                                               =============  =============

Adjusted Non-GAAP Basic Earnings (Loss) per
 share:
GAAP net loss per common share-basic and
 diluted                                       $       (3.07) $       (0.36)
  Non-GAAP adjustments                                  3.23           0.06
                                               -------------  -------------
  Adjusted Non-GAAP Basic Earnings (Loss) per
   share                                       $        0.16  $       (0.30)

Adjusted Non-GAAP Diluted Net Income (Loss)
 Per Share:
Adjusted Non-GAAP net income (loss) per common
 share-basic                                   $        0.16  $       (0.30)
  Dilutive earnings per share effect of common
   stock equivalents                                   (0.03)             -
                                               -------------  -------------
  Adjusted Non-GAAP net income (loss) per
   common share-diluted                        $        0.13  $       (0.30)



                ADDITIONAL GAAP TO NON-GAAP RECONCILIATIONS
                     (in thousands, except percentages)

                                               Three Months Ended March 31,
                                               ----------------------------
                                                    2014           2013
                                               -------------  -------------
                                                        (Unaudited)

GAAP Net Loss                                  $    (206,250) $     (22,171)

Loss on derivative revaluation                       204,030              -
Depreciation and intangible amortization
 expense                                               5,403          1,922
Interest expense, net                                  4,207          3,603
Other expense, net                                       667              -
Foreign exchange loss                                     38            905
Benefit for income taxes                              (1,105)          (881)
                                               -------------  -------------
      Non-GAAP Adjustments                           213,240          5,549
                                               -------------  -------------
EBITDA                                         $       6,990  $       1,079
                                               -------------  -------------
  Adjustments for Vidara acquisition costs             4,049              -
                                               -------------  -------------
      Total Non-GAAP Adjustments                     217,289          5,549
                                               -------------  -------------
Adjusted EBITDA                                $      11,039  $       1,079
                                               =============  =============

GAAP net sales                                 $      51,926  $       8,693
GAAP cost of goods sold                               (7,619)        (3,769)
                                               -------------  -------------
GAAP gross profit                              $      44,307  $       4,924
                                               -------------  -------------

GAAP gross profit %                                       85%            57%

Non-GAAP gross profit adjustments:
  Depreciation and intangible amortization
   expense                                             5,059          1,716
                                               -------------  -------------
Non-GAAP gross profit                          $      49,366  $       6,640
                                               -------------  -------------

Non-GAAP gross profit %                                   95%            76%

GAAP cash used in operating activities         $        (757) $     (22,769)
  Cash payments related to Vidara acquistion           5,095              -
                                               -------------  -------------
Non-GAAP cash used in operating activities     $       4,338  $     (22,769)
                                               -------------  -------------



              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                               (in thousands)

                                               Three Months Ended March 31,
                                               ----------------------------
                                                    2014           2013
                                               -------------  -------------
                                                        (Unaudited)
Cash flows from operating activities
Net loss                                       $    (206,250) $     (22,171)
Adjustments to reconcile net loss to net cash
 used in operating activities
  Depreciation and amortization                        5,403          1,922
  Stock-based compensation                             1,927          1,079
  Loss on derivative revaluation                     204,030              -
  Amortization of debt discount and deferred
   financing costs                                     2,333            910
  Paid in kind interest expense                            -            783
  Foreign exchange loss                                   38            905
  Changes in operating assets and liabilities:
    Accounts receivable                              (24,142)        (4,300)
    Inventories                                         (729)           866
    Prepaid expenses and other current assets         (4,218)           379
    Accounts payable                                     352         (1,026)
    Accrued expenses                                  20,702         (1,682)
    Deferred revenues                                    112            349
    Deferred tax liabilities                            (454)          (864)
    Other non-current assets and liabilities             139             81
                                               -------------  -------------
      Net cash used in operating activities             (757)       (22,769)
                                               -------------  -------------
Cash flows from investing activities
Purchase of property and equipment                      (494)          (225)
                                               -------------  -------------
      Net cash used in investing activities             (494)          (225)
                                               -------------  -------------
Cash flows from financing activities
Proceeds from the issuance of common stock            24,156              -
                                               -------------  -------------
      Net cash provided by financing
       activities                                     24,156              -
                                               -------------  -------------
Effect of exchange rate changes on cash and
 cash equivalents                                        (11)           (17)
      Net increase (decrease) in cash and cash
       equivalents                                    22,894        (23,011)
Cash and cash equivalents
Beginning of period                                   80,480        104,087
                                               -------------  -------------
End of period                                  $     103,374  $      81,076
                                               =============  =============

Contact:

Robert J. De Vaere
Executive Vice President, Chief Financial Officer
Email Contact

Bob Carey
Executive Vice President, Chief Business Officer
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...